Inhibrx Biosciences Inc
INBX80.210USD
-0.150-0.19%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
1.16BMarket Cap
LossP/E TTM
More Details of Inhibrx Biosciences Inc Company
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Its clinical pipeline of therapeutic candidates includes ozekibart (INBRX-109) and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that it designed with its proprietary single domain antibody (sdAb) platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist which is being investigated as a single agent and in combination with KEYTRUDA (pembrolizumab), a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors.
Inhibrx Biosciences Inc Info
Ticker SymbolINBX
Company nameInhibrx Biosciences Inc
IPO dateMay 28, 2024
CEOLappe (Mark P)
Number of employees156
Security typeOrdinary Share
Fiscal year-endMay 28
Address11025 N. Torrey Pines Road, Suite 140
CityLA JOLLA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92037
Phone18587954220
Websitehttps://inhibrx.com/
Ticker SymbolINBX
IPO dateMay 28, 2024
CEOLappe (Mark P)
Company Executives of Inhibrx Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Jon Faiz Kayyem, Ph.D.
Dr. Jon Faiz Kayyem, Ph.D.
Independent Director
Independent Director
1.06M
-7.83%
Ms. Kimberly J. Manhard
Ms. Kimberly J. Manhard
Independent Director
Independent Director
10.00K
--
Mr. David J. Matly
Mr. David J. Matly
President, Chief Commercial and Business Development Officer
President, Chief Commercial and Business Development Officer
--
--
Mr. Mark P. Lappe
Mr. Mark P. Lappe
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Kristiina S. Vuori, M.D., Ph.D.
Dr. Kristiina S. Vuori, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Kelly D. Deck, CPA
Ms. Kelly D. Deck, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Douglas G. Forsyth
Mr. Douglas G. Forsyth
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Jon Faiz Kayyem, Ph.D.
Dr. Jon Faiz Kayyem, Ph.D.
Independent Director
Independent Director
1.06M
-7.83%
Ms. Kimberly J. Manhard
Ms. Kimberly J. Manhard
Independent Director
Independent Director
10.00K
--
Mr. David J. Matly
Mr. David J. Matly
President, Chief Commercial and Business Development Officer
President, Chief Commercial and Business Development Officer
--
--
Mr. Mark P. Lappe
Mr. Mark P. Lappe
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Kristiina S. Vuori, M.D., Ph.D.
Dr. Kristiina S. Vuori, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Kelly D. Deck, CPA
Ms. Kelly D. Deck, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
FY2025Q2
FY2024
FY2023
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
1.30M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Viking Global Investors LP
9.89%
Perceptive Advisors LLC
9.13%
Sanofi SA
7.96%
Kayyem (Jon Faiz)
7.28%
Lappe Mark
6.53%
Other
59.21%
Shareholders
Shareholders
Proportion
Viking Global Investors LP
9.89%
Perceptive Advisors LLC
9.13%
Sanofi SA
7.96%
Kayyem (Jon Faiz)
7.28%
Lappe Mark
6.53%
Other
59.21%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
19.23%
Individual Investor
19.10%
Investment Advisor
18.52%
Hedge Fund
9.80%
Private Equity
9.13%
Corporation
7.96%
Research Firm
3.63%
Venture Capital
3.03%
Bank and Trust
0.28%
Other
9.32%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
195
9.60M
66.26%
-2.53M
2025Q2
196
13.69M
94.56%
-1.66M
2025Q1
194
14.95M
103.28%
-332.98K
2024Q4
178
13.97M
96.51%
+959.14K
2024Q3
164
12.65M
87.38%
+1.96M
2024Q2
138
13.13M
90.69%
+8.92M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Viking Global Investors LP
1.79M
12.34%
--
--
Jun 30, 2025
Perceptive Advisors LLC
977.89K
6.75%
-86.13K
-8.10%
Jun 30, 2025
Sanofi SA
1.16M
7.99%
--
--
Jun 30, 2025
Kayyem (Jon Faiz)
1.06M
7.31%
-90.00K
-7.83%
Apr 01, 2025
Lappe Mark
950.41K
6.56%
+25.00K
+2.70%
Apr 01, 2025
Hightower Advisors, LLC
871.76K
6.02%
+5.00
+0.00%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
665.03K
4.59%
-102.08K
-13.31%
Jun 30, 2025
The Vanguard Group, Inc.
598.45K
4.13%
+10.13K
+1.72%
Jun 30, 2025
Eckelman (Brendan P)
513.89K
3.55%
--
--
Apr 01, 2025
Sofinnova Investments, Inc
708.68K
4.89%
+10.76K
+1.54%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
WisdomTree US SmallCap Fund
0.31%
ProShares Ultra Nasdaq Biotechnology
0.15%
iShares Micro-Cap ETF
0.14%
Invesco Nasdaq Biotechnology ETF
0.12%
Fidelity Enhanced Small Cap ETF
0.12%
iShares Biotechnology ETF
0.07%
iShares Russell 2000 Value ETF
0.05%
Invesco RAFI US 1500 Small-Mid ETF
0.04%
Proshares Ultra Russell 2000
0.03%
Global X Russell 2000 ETF
0.03%
View more
WisdomTree US SmallCap Fund
Proportion0.31%
ProShares Ultra Nasdaq Biotechnology
Proportion0.15%
iShares Micro-Cap ETF
Proportion0.14%
Invesco Nasdaq Biotechnology ETF
Proportion0.12%
Fidelity Enhanced Small Cap ETF
Proportion0.12%
iShares Biotechnology ETF
Proportion0.07%
iShares Russell 2000 Value ETF
Proportion0.05%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.04%
Proshares Ultra Russell 2000
Proportion0.03%
Global X Russell 2000 ETF
Proportion0.03%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Inhibrx Biosciences Inc?
The top five shareholders of Inhibrx Biosciences Inc are:
Viking Global Investors LP holds 1.79M shares, accounting for 12.34% of the total shares.
Perceptive Advisors LLC holds 977.89K shares, accounting for 6.75% of the total shares.
Sanofi SA holds 1.16M shares, accounting for 7.99% of the total shares.
Kayyem (Jon Faiz) holds 1.06M shares, accounting for 7.31% of the total shares.
Lappe Mark holds 950.41K shares, accounting for 6.56% of the total shares.
Viking Global Investors LP holds 1.79M shares, accounting for 12.34% of the total shares.
Perceptive Advisors LLC holds 977.89K shares, accounting for 6.75% of the total shares.
Sanofi SA holds 1.16M shares, accounting for 7.99% of the total shares.
Kayyem (Jon Faiz) holds 1.06M shares, accounting for 7.31% of the total shares.
Lappe Mark holds 950.41K shares, accounting for 6.56% of the total shares.
What are the top three shareholder types of Inhibrx Biosciences Inc?
The top three shareholder types of Inhibrx Biosciences Inc are:
Viking Global Investors LP
Perceptive Advisors LLC
Sanofi SA
Viking Global Investors LP
Perceptive Advisors LLC
Sanofi SA
How many institutions hold shares of Inhibrx Biosciences Inc (INBX)?
As of 2025Q3, 195 institutions hold shares of Inhibrx Biosciences Inc, with a combined market value of approximately 9.60M, accounting for 66.26% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -28.30%.
What is the biggest source of revenue for Inhibrx Biosciences Inc?
In FY2025Q2, the -- business generated the highest revenue for Inhibrx Biosciences Inc, amounting to -- and accounting for --% of total revenue.
